UTRN and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: We conclude that the enhanced protein transduction gained by reducing the molecular weight of utrophin overcomes any loss of TAT-μUtr's biological function and propose TAT-μUtr as a potential direct protein replacement therapy for dystrophinopathies.